# Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

> **NCT03179787** · — · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 528 (actual)

## Conditions studied

- Autism

## Interventions

- **DRUG:** Aripiprazole oral product

## Key facts

- **NCT ID:** NCT03179787
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-07-06
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179787, "Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03179787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*